# LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

> **NCT01820364** · PHASE2 · TERMINATED · sponsor: **Array BioPharma** · enrollment: 15 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** LGX818

## Key facts

- **NCT ID:** NCT01820364
- **Lead sponsor:** Array BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Study was withdrawn due to scientific and business considerations.
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820364, "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01820364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*